EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation

Yizhuo Wang, Chenwu Bai, Kerui Hou, Zhen Zhang, Ming Guo, Xin Wang, Fan Yang, Xin Liu iD

Advanced Science · 2025

DOI: 10.1002/advs.202504690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yizhuo Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: COVID-19, Spike Glycoprotein, Coronavirus, SARS-CoV-2, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complement dysregulation and immune hyperactivation are pivotal factors contributing to the mortality associated with SARS‐CoV‐2 infection. Engineered Antibody‐like proteins (ALPs) targeting the SARS‐CoV‐2 spike protein are engineered to address immune dysregulation in COVID‐19. In this study, Lectifitin‐36 and Lectifitin‐41, two such ALPs, are developed using cDNA display technology. These ALPs demonstrate strong binding affinity for the spike protein and effectively inhibit its interaction with ACE2 and several C‐type lectins, including MBL, DC‐SIGN, and L‐SIGN. Both in vitro and in vivo analyses reveal that Lectifitin‐36 and Lectifitin‐41 suppress complement activation via the lectin pathway, reduce neutrophil extracellular trap (NET) formation, and attenuate hyper‐inflammatory responses. In mouse models, Lectifitin‐36 and Lectifitin‐41 significantly mitigate inflammation, NETosis, and lung tissue damage induced by the spike protein. These results suggest that these ALPs hold promise as therapeutic candidates for alleviating SARS‐CoV‐2‐induced immune dysfunction, with the potential to reduce severe COVID‐19 outcomes and long‐term sequelae. This study underscores the therapeutic potential of targeting spike protein‐mediated immune modulation as an innovative approach to combat COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Spike Glycoprotein, CoronavirusSARS-CoV-2InflammationCOVID-19 Drug TreatmentAnimalsMiceHumansProtein EngineeringExtracellular TrapsAngiotensin-Converting Enzyme 2Complement ActivationDisease Models, Animal

Stichwörter der Autor:innen

SARS‐CoV‐2antibody‐like proteinimmune dysregulationmannose‐binding lectinspike protein

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Angiotensin-Converting Enzyme 2

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, 430071, China.
  • Institute for Vaccine Research, Animal Bio-Safety Level III Laboratory / Center for Animal Experiment, Wuhan University School of Medicine, Wuhan, 430071, China.
  • State Key Laboratory of Virology and Biosafety, Modern Virology Research Center and RNA Institute, College of Life Sciences, Wuhan University, Wuhan, 430071, China.
  • Departmant of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430021, China.

ORCID-Profile: Xin Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Bai, C., Hou, K., Zhang, Z., Guo, M., Wang, X., Yang, F., & Liu, X. (2025). Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation. Advanced Science. https://doi.org/10.1002/advs.202504690

Vancouver

Wang Y, Bai C, Hou K, Zhang Z, Guo M, Wang X, et al. Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation. Advanced Science. 2025. doi:10.1002/advs.202504690

BibTeX
@article{Wang2025,
  author = {Wang, Yizhuo and Bai, Chenwu and Hou, Kerui and Zhang, Zhen and Guo, Ming and Wang, Xin and Yang, Fan and Liu, Xin},
  title = {Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202504690}
}
Kostenlos starten →